Trevor Hawkins will leave his post as director of the DOE’s Joint Genome Institute on March 1 to become senior vice president of genomics at Amersham Biosciences. Hawkins said he would split his time between the two appointments while the DOE searches for a new director. He plans to continue to function as director of the JGI until at least Sept. 1, if a new director has not yet been named.
Madison, Wis.-based EraGen Biosciences has selected Irene Hrusovsky as president and CEO. Hrusovsky, who has also been appointed to the company’s board of directors, was most recently vice president of general medicine, medical marketing strategy, and clinical operations at GlaxoSmithKline.
EraGen’s former president and CEO, Gideon Shapiro, stepped down last February.
Chi-Chi Zhu, formerly director of business development for Celera Genomics, has been appointed vice president of business development at Brighton, Mass.-based Surface Logix, a developer of biological microsystems to detect disease processes.
Gene Logic of Gaithersburg, Md., has appointed J. Stark Thompson to its board of directors. Stark managed several domestic and international businesses at DuPont for twenty-one years before leaving his position there in 1988 to serve as president and CEO of Life Technologies.
Mats Grahn, vice president of proteomics product management at Amersham Biosciences, has joined the board of Copenhagen, Denmark-based Prevas Bioinformatics. Grahn was previously business area manager at Prevas and was also responsible for establishing the company in Denmark.
Michael Tracy, former vice president of SRI International’s pharmaceutical discovery division is now vice president for corporate business development in biotechnology. In this role, Tracy will be responsible for strategic initiatives in biotechnology, bioinformatics, and proteomics.